Camille G. Frazier

Closing the gap: treating hypertension in women.

Hypertension is a common and readily modifiable risk factor for cardiovascular and cerebrovascular disease. Despite extensive clinical trial results and efforts to increase public awareness, it remains inadequately controlled in the general population. Women are particularly vulnerable. Recent data indicate both a growing prevalence of hypertension, particularly in the postmenopausal and African American populations, and significantly lower rates of adequate blood pressure control relative to men. Patient sex has an important influence on the nature of the disease, its management, and outcomes. This review will focus on sex-specific factors that contribute to hypertension in women, and current patterns and efficacy of treatment. In addition, we will highlight evidence-based options for antihypertensive treatment in women.

Microarrays Coming of Age in Cardiovascular Medicine: Standards, Predictions, and Biology⁎

High-density microarray, or so-called “gene chip,” experiments, wherein the levels of expression of the ∼25,000 human genes is measured using RNA isolated from a tissue or cell, is now commonplace and uniquely adaptable to a broad array of medical and biologic questions. For example, the

Clinical ResearchHeart Failure: Editorial CommentMicroarrays Coming of Age in Cardiovascular Medicine: Standards, Predictions, and Biology⁎

High-density microarray, or so-called “gene chip,” experiments, wherein the levels of expression of the ∼25,000 human genes is measured using RNA isolated from a tissue or cell, is now commonplace and uniquely adaptable to a broad array of medical and biologic questions. For example, the

Microarrays Coming of Age in Cardiovascular Medicine. Standards, Predictions, and Biology**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

High-density microarray, or so-called “gene chip,” experiments, wherein the levels of expression of the ∼25,000 human genes is measured using RNA isolated from a tissue or cell, is now commonplace and uniquely adaptable to a broad array of medical and biologic questions. For example, the

Microarrays Coming of Age in Cardiovascular Medicine

High-density microarray, or so-called “gene chip,” experiments, wherein the levels of expression of the ∼25,000 human genes is measured using RNA isolated from a tissue or cell, is now commonplace and uniquely adaptable to a broad array of medical and biologic questions. For example, the